about
Transoesophageal echocardiography during liver transplantationHepato-cardiac disordersCardiovascular dysfunction in patients with liver cirrhosisRole of cardiovascular intervention as a bridge to liver transplantationThe Correlation between Echocardiographic Findings and QT Interval in Cirrhotic Patients.Cardiac dysfunction in cirrhotic portal hypertension with or without ascites.Liver cirrhosisQuantifying memory in complex physiological time-series.Endocannabinoids in liver disease.Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy.Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis.The end-organ impairment in liver cirrhosis: appointments for critical care.Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.High Flow-Mediated Vasodilatation Predicts Pulmonary Edema in Liver Transplant Patients.Pathophysiological aspects of pulmonary complications of cirrhosis.Cardiovascular determinants of survival in cirrhosis.N-terminal pro B-type natriuretic peptide and the evaluation of cardiac dysfunction and severity of disease in cirrhotic patientsCardiac structural and functional alterations in infants and children with biliary atresia, listed for liver transplantationThe endocannabinoid system and liver diseases.Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis.Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoidsDiastolic dysfunction and severity of cirrhosis in nonalcoholic cirrhotic patientsEndocannabinoids and cardiac contractile function: pathophysiological implications.Interactions of the heart and the liver.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspectsCirrhotic Multiorgan Syndrome.The Relationship between QT Interval Dispersion and End-Stage Liver Disease Score in the Patients Undergoing Orthotopic Liver Transplantation.Diastolic dysfunction in cirrhosis.Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis?Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosisHypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosisStroke volume response to liver graft reperfusion stress in cirrhotic patients.Endocannabinoid-related compounds in gastrointestinal diseases.Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations.The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis.N-Terminal pro-B-Type Natriuretic Peptide Levels are Linked with Modified Child-Pugh Classification in Patients with Nonalcoholic Cirrhosis [NT-ProBNP and Liver Cirrhosis].Left Ventricular Myocardial Mechanics in Cirrhosis: A Speckle Tracking Echocardiographic Study.Cardiac abnormalities in cirrhotic children: pre- and post-liver transplantation.
P2860
Q26781485-BBFD4368-427F-4AD6-8D14-E0E7C28D4D96Q26997114-342282EE-44F5-42CF-8F38-BA55D003CE00Q27010592-372D1CEB-07D4-4224-9EA7-5AF3D26C8FACQ27011341-512EAAE4-0C64-4418-B579-3599B0D2635CQ33758733-5B76FF1C-C5AC-46C3-A303-0BFC91068959Q33813433-2014BD9B-7D89-44F1-A062-1558D02378ADQ34010340-0D24E7F9-CE4E-47F7-927F-A409874DDF08Q34371489-058AF9F4-74B4-4074-8C92-08060372870AQ34776919-43BFC576-1DCE-474E-BD1C-E5B6FCCBCB48Q34885329-3F44FF1E-DD67-48E8-A025-F8DF4CB770DBQ35833011-C7B40B46-0C62-4B8E-993A-32E190CF7EC8Q35993701-EE301106-3ACE-4149-A684-0D80A1BB374FQ36426811-CF7A4EA3-C960-4017-95FF-B13BC99731B1Q36721334-E738EFF5-335D-47B2-8F98-C08761EA6E81Q36799915-E2A0B580-30F8-4882-9372-4A06DE2634D3Q36829265-62AAB435-1AD8-45D7-B2FA-CDF783750FD5Q37040910-4D1493A0-6E73-4028-ABEE-DADB3D1E7E88Q37087807-22FB9B73-19CD-4CC0-931D-1DB8A066AB93Q37143574-0F4EC3AA-527C-4459-A45E-E0A63C2E5C99Q37243665-76E3424D-5D87-42F6-A454-BA048CACA7C7Q37301437-3464AC24-0CFE-44CE-A67B-4FB660B0121BQ37385716-4A60B705-71FA-4ADB-9413-2AC536097451Q37401757-C3074251-56AC-4C38-A9C1-6A8D6D3FDD77Q38121525-5A8D4495-7C03-4BC5-8907-F6A752EEACBAQ38124458-102D5501-AF3A-4151-96F7-F5EE495C6402Q38268612-54FBFF39-9A26-436A-AA37-1C8400D082A8Q38538183-5B89A9E4-E6F2-457E-8EA9-7E58546A9607Q38764786-7B36E45C-6DB8-47DC-998C-9F2C2991E0F2Q38881630-1CE3196C-3324-4C8C-961F-FCEF3A726F89Q40029009-F98EEA59-A4D8-4AFF-8506-264C0C338B50Q40931180-0E65B1DB-3407-4693-BE3B-B1C727A43784Q42124714-79673E7C-5EB6-4DC2-874F-3FC54475D6ECQ44016636-3E449EF1-45E4-4AAF-BD09-441DF1FBFDEBQ47839554-3C7F1712-F0EA-4A34-BA78-C4D8027915D9Q47912085-C4EFC167-45BF-44FC-84D1-AC59C137CAB6Q48331734-1EBE05ED-E385-495C-88DA-1342F7FC3513Q48407843-A25DF745-153F-49A5-AADA-E4087E52ACD7Q48661128-5E457EAD-4BCA-4897-B8F7-6AF220300871Q50972269-B370EB20-3D3C-45C1-9044-56672374B748
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Therapy insight: Cirrhotic cardiomyopathy.
@ast
Therapy insight: Cirrhotic cardiomyopathy.
@en
type
label
Therapy insight: Cirrhotic cardiomyopathy.
@ast
Therapy insight: Cirrhotic cardiomyopathy.
@en
prefLabel
Therapy insight: Cirrhotic cardiomyopathy.
@ast
Therapy insight: Cirrhotic cardiomyopathy.
@en
P2093
P2860
P356
P1476
Therapy insight: Cirrhotic cardiomyopathy.
@en
P2093
Hooman Honar
Samuel S Lee
Seyed A Gaskari
P2860
P2888
P304
P356
10.1038/NCPGASTHEP0498
P407
P577
2006-06-01T00:00:00Z